HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Market Cap	$9.31M	P/E Ratio	NaN
52W High	$2.80	52W Low	$0.72
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-14.7%	52W Position	7.6%

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HOOK	$0.88	-0.15%	4.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HOOK	$0.88	-0.1%	4.00K
3
4
5
6

HOOK

HOOK

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get HOOKIPA Pharma Inc. Data in Excel

Get HOOKIPA Pharma Inc. Data in Excel